Concepedia

Donna Headlee

DH

Statistics

Publications

31

Citations

3.1K

H-Index

25

Active since

1992

Affiliations

National Cancer Institute(Current)

National Institutes of Health

Center for Cancer Research

National Institutes of Health Clinical Center

National Cancer Institute

Donna Headlee is an author at National Cancer Institute specializing in medicine, oncology, and pharmacology.

Top concepts

Publications per year

1992–2014

31

Publications

31

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson et al. · Journal of Clinical Oncology · 1998 · 408 citations

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Qin Ryan, Donna Headlee, Milin Acharya et al. · Journal of Clinical Oncology · 2005 · 406 citations · Full text

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Edward A. Sausville, Susan G. Arbuck, Richard A. Messmann et al. · Journal of Clinical Oncology · 2001 · 294 citations

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Eiichi Fuse, Hiromi Tanii, Noriaki Kurata et al. · PubMed · 1998 · 203 citations

, , +14

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study

EA Sausville, Donna Headlee, M Stetler-Stevenson et al. · Blood · 1995 · 164 citations · Full text

Rows per page

1–5 of 31